Drugs / JR-131
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02912533 | Sep 2016 → Mar 2018 | anemia | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02912494 | Sep 2016 → Sep 2017 | anemia | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-01-17 | Kissei Pharmaceutical Co., Ltd. | Results 持続型赤血球造血刺激因子製剤「JR-131（開発番号）」第Ⅲ相臨床試験結果のお知らせ kissei.co.jp ↗
その結果、有効性の主要評価項目であるヘモグロビン濃度変化量における同等性が検証され、安全性プロファイルの類似性も確認されました。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-01-17 | Kissei Pharmaceutical Co., Ltd. | 持続型赤血球造血刺激因子製剤「JR-131（開発番号）」第Ⅲ相臨床試験結果のお知らせ kissei.co.jp ↗ |
| 2016-08-09 | Kissei Pharmaceutical Co., Ltd. | 持続型赤血球造血刺激因子製剤「JR-131（開発番号）」 第Ⅲ相臨床試験開始のお知らせ kissei.co.jp ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JR-131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02912533 ↗ |